Catalyst Health Ventures invests in disruptive solutions for unmet healthcare needs and is a Massachusetts-based venture capital firm.
Business Model:
Revenue: $0
Employees: 0-0
Address: 50 Braintree Hill Office Park
City: Braintree
State: MA
Zip: 02184
Country: US
Catalyst Health Ventures is an early-stage venture capital firm targeting technology solutions applied within the health care and life science industries. At the core of this strategy is a committed, hands-on approach to working with management and syndicate partners to build successful companies. Their disciplined investment process leverages both intellectual and financial capital to originate deals, cultivate opportunities, and realize the full potential of emerging ventures in the health care and life science marketplace. We seek to invest in companies addressing major global unmet clinical needs in areas such as oncology, cardiovascular disease, obesity, and women’s health. We invest in pioneering and proprietary technological solutions fundamentally designed to reduce treatment costs and improve patient outcomes. By investing in solutions which have a technological foundation of engineering and development such as medical devices, diagnostic tools and instrumentation and consumer healthcare, we minimize the risks related to uncertain scientific experimentation.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
8/2020 | Conformal Medical | Series C | 85M |
11/2010 | Sera Prognostics | Seed Round | - |
7/2014 | SpaceOAR | Series D | 0 |
7/2016 | nVision Medical | Series B | 12M |
1/2017 | Sera Prognostics | Series C | 22M |
12/2011 | nVision Medical | Seed Round | 125k |
12/2013 | Maxwell Health | Series A | 6M |
2/2022 | Epitel | Series A | 0 |
1/2012 | BIOCIUS Life Sciences | Venture Round | - |
12/2014 | Maxwell Health | Series B | 26.4M |
9/2010 | Lantos Technologies | Venture Round | 1.6M |
3/2022 | Avive Solutions | Series A | 0 |
1/2015 | Sera Prognostics | Series B | 20M |
11/2014 | Sera Prognostics | Series B | 5M |
8/2011 | Lantos Technologies | Venture Round | 4.1M |
3/2016 | Maxwell Health | Series C | 0 |
4/2020 | AtaCor Medical | Series B | 0 |
7/2011 | Allegro Diagnostics | Series A | 5.4M |
4/2015 | Saphena Medical | Series B | 1.8M |
11/2011 | Sera Prognostics | Series A | 19.3M |
10/2020 | Instylla | Series B | 0 |
3/2010 | Vortex Medical | Series B | - |
10/2009 | SpaceOAR | Series B | 6.1M |
12/2018 | Conformal Medical | Series B | 9M |
3/2008 | Vortex Medical | Series A | 2.3M |
9/2017 | Saphena Medical | Series C | 1.3M |
12/2014 | SevenOaks BioSystems | Series A | 1M |
4/2013 | nVision Medical | Series A | 0 |
2/2020 | Aria CV | Series B | 0 |
5/2021 | PanTher Therapeutics | Series A | 5.4M |
9/2013 | Cruzar Medsystems | Series A | 2.9M |
1/2011 | SpaceOAR | Debt Financing | 3M |
7/2016 | SpaceOAR | Series E | 6M |
3/2018 | Lantos Technologies | Venture Round | 0 |
7/2015 | Aria CV | Series A | 7.8M |
1/2011 | Sera Prognostics | Series A | 1.4M |
6/2017 | Cruzar Medsystems | Series B | 2.3M |
12/2022 | Rejoni | Series B | 0 |
3/2022 | Avive Solutions | Series A | 0 |
2/2022 | Epitel | Series A | 0 |
5/2021 | PanTher Therapeutics | Series A | 0 |
10/2020 | Instylla | Series B | 0 |
4/2020 | AtaCor Medical | Series B | 0 |
2/2020 | Aria CV | Series B | 0 |
12/2018 | Conformal Medical | Series B | 0 |
3/2018 | Lantos Technologies | Venture Round | 0 |
9/2017 | Saphena Medical | Series C | 0 |
6/2017 | Cruzar Medsystems | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|